UNSPSC 51311602: Efletirizine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B6C301298G. European Medicines Agency schedules Efletirizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06467MIG. Efletirizine generally arises in the molecular formula C21H24F2N2O3.

UNSPSC 51311602 Efletirizine is a Commodity code that in practice does not align with the state and local opportunities currently tagged to it. The recent opportunities show pharmaceutical procurement activity — naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals — but none explicitly involve efletirizine as a product line. Seminole County, Florida issued an IFB on June 30, 2026 for naloxone and drug deactivation systems (1,900 units naloxone and 800 deactivation systems annually) with a response deadline of July 26, 2023; the Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription fulfillment; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026.

The issuing bodies span state health agencies, county health departments, and multi-state cooperative purchasing alliances; the geographic footprint includes Texas, Minnesota, Oregon, and Florida, with MMCAP serving a multi-state membership. The mismatch between the Commodity code name and the actual solicitation content suggests that efletirizine procurement under this code shows little relevant recent activity in state and local government markets. Procurement professionals should verify whether opportunities currently tagged to this code genuinely involve efletirizine supply or whether the tag reflects a cataloging error; the available recent solicitations do not support active demand for efletirizine specifically.